Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failureYuliya Lytvyn, David Z.I. Cherney, Luxcia Kugathasan et al.|Physiological Reports|2025Cited by 5
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled TrialVikas S. Sridhar, David Z.I. Cherney, Luxcia Kugathasan et al.|Hypertension|2025Cited by 1